Abstract 102P
Background
Patients with long-standing Crohn’s disease (CD) are at a high risk of development of anorectal cancer (ARC), however, the clinical features of ARC complicating CD are still uncertain. The aim of the present study was to clarify the clinical features of ARC complicating CD.
Methods
From 1995 to 2018, 483 patients with CD underwent surgery in our hospital. Of the 483 patients, 14 patients (2.9%) were diagnosed with ARC. A detailed review of the medical records of the patients was undertaken.
Results
The median age at diagnosis of ARC was 45 years (25-72 yrs). The median time interval between the diagnosis of CD and ARC was 21 years (7-40 yrs). Eight patients had fecal diversion because of their perianal disease. Ten patients had cancer-related symptoms. The other 4 patients had no cancer-related symptom, but serum CEA was elevated in the 2 of the 4 patients. The 4 patients were diagnosed by cancer surveillance biopsy and 3 of the 4 patients (75%) underwent R0 resection. On the other hand, only 2 of the 10 patients (20%) underwent R0 resection in patients who had cancer-related symptom at the diagnosis of ARC. The surgical procedures were as follows: abdominoperineal resection (n = 6), total pelvic exenteration (n = 3), total proctocolectomy (n = 1), loop ileostomy (n = 3), and exploratory laparotomy (n = 1). UICC staging was as follows: stage I;2. stageII;3, stageIII;4, stageIV;5. After the surgery, chemoradiotherapy was performed in 4 patients, chemotherapy in 4, and radiotherapy in 1. All the patients who underwent R0 resection achieved 5-year relapse free survival, while the 1-year / 2-year overall survival rate of the patients’ group who underwent R1 and R2 resection was 75%/50% (R1) and 40%/0% (R2), respectively.
Conclusions
ARC was not rare in the patients with long-standing CD. The prognosis is poor in patients’ group with R1/R2 resection, while, patients’ group who achieved R0 resection is good. There is a pressing need to develop strategies for the early detection of ARC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract